No Data
No Data
Oppenheimer Keeps Their Buy Rating on CalciMedica (CALC)
CALC (01848.HK) will hold a Board of Directors meeting on March 18 to approve the annual performance.
On March 5, Gelonghui reported that CALC (01848.HK) announced that the Board of Directors will hold a meeting on March 18, 2025, to approve (including) the audited annual performance of the company and its subsidiaries for the year ending December 31, 2024, and to consider the proposal for the final dividend distribution (if any).
CALC: DATE OF BOARD MEETING
China Aircraft Leasing Subsidiary Gets New Chairman
CalciMedica, Inc. (CALC): Among Penny Stocks With Insider Buying in 2025
Behind the investment-grade credit rating, what are the value highlights of CALC (01848.HK)?
In the investment field, credit ratings not only serve as an important measure of a company's overall strength and future development potential, but they are also a core basis for investors to assess a company's credit risk, investment value, and long-term competitiveness, profoundly impacting the company's financing ability, brand image, and market expansion. Recently, a new credit rating for CALC has attracted widespread attention in the market. It is reported that this is the first collaboration between the company and an Overseas rating agency, which has significant Global Strategy implications. It is worth mentioning that when CCXI Asia Pacific first rated CALC, it granted an investment-grade rating directly, fully demonstrating the market's confidence in the company.